Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MZOR
Previous Symbol
CUSIPN/A
Phone972-4618-7101
Debt
Debt-to-Equity RatioN/A
Current Ratio5.49
Quick Ratio5.18
Price-To-Earnings
Trailing P/E Ratio-116.42
Forward P/E Ratio-232.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.95 million
Price / Sales23.60
Cash FlowN/A
Price / CashN/A
Book Value$4.46 per share
Price / Book13.05
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-12,410,000.00
Net Margins-37.29%
Return on Equity-7.70%
Return on Assets-6.64%
Miscellaneous
Employees194
Outstanding Shares26,330,000
Market Cap$1.53 billion
OptionableOptionable
Mazor Robotics (NASDAQ:MZOR) Frequently Asked Questions
What is Mazor Robotics' stock symbol?
Mazor Robotics trades on the NASDAQ under the ticker symbol "MZOR."
How were Mazor Robotics' earnings last quarter?
Mazor Robotics Ltd - (NASDAQ:MZOR) issued its quarterly earnings data on Thursday, August, 2nd. The medical instruments supplier reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.13. The medical instruments supplier earned $13.20 million during the quarter, compared to analysts' expectations of $17.02 million. Mazor Robotics had a negative return on equity of 7.70% and a negative net margin of 37.29%. The company's revenue was down 14.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) earnings per share. View Mazor Robotics' Earnings History.
When is Mazor Robotics' next earnings date?
What price target have analysts set for MZOR?
4 brokerages have issued twelve-month price targets for Mazor Robotics' stock. Their predictions range from $36.00 to $62.00. On average, they anticipate Mazor Robotics' stock price to reach $51.6667 in the next year. This suggests that the stock has a possible downside of 11.2%. View Analyst Price Targets for Mazor Robotics.
What is the consensus analysts' recommendation for Mazor Robotics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mazor Robotics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mazor Robotics.
What are Wall Street analysts saying about Mazor Robotics stock?
Here are some recent quotes from research analysts about Mazor Robotics stock:
- 1. According to Zacks Investment Research, "Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. " (11/15/2018)
- 2. Needham & Company LLC analysts commented, "MZOR reported revenue and EPS that were below consensus. On 11/19/18, MZOR will hold a shareholder vote to confirm MDT’s proposed acquisition. We see no reason to believe the deal will not be confirmed and we maintain our Hold rating." (11/7/2018)
Has Mazor Robotics been receiving favorable news coverage?
Media coverage about MZOR stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mazor Robotics earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Mazor Robotics' key competitors?
Some companies that are related to Mazor Robotics include Haemonetics (HAE), Globus Medical (GMED), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Atrion (ATRI) and AtriCure (ATRC).
Who are Mazor Robotics' key executives?
Mazor Robotics' management team includes the folowing people:
- Mr. Ori Hadomi, CEO & Director (Age 51)
- Mr. Eliyahu Zehavi, Co-Founder & Exec. VP of Advanced Technologies (Age 63)
- Ms. Sharon Levita, CFO, VP of Bus. Operations & Company Sec. (Age 51)
- Dr. Doron Dinstein M.D., Chief Medical Officer (Age 47)
- Mr. Christopher Prentice, Chief Commercial Officer (Age 48)
Who are Mazor Robotics' major shareholders?
Mazor Robotics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (7.90%), FIL Ltd (5.32%), Mirae Asset Global Investments Co. Ltd. (2.34%), Nuance Investments LLC (1.96%), Gabelli Funds LLC (0.87%) and Sumitomo Mitsui Trust Holdings Inc. (0.57%).
Which major investors are selling Mazor Robotics stock?
MZOR stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Morgan Stanley, Dorsey Wright & Associates, Sumitomo Mitsui Trust Holdings Inc., Wells Fargo & Company MN, American National Bank and Biondo Investment Advisors LLC.
Which major investors are buying Mazor Robotics stock?
MZOR stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Mirae Asset Global Investments Co. Ltd., Credit Suisse AG, Nuance Investments LLC, Gabelli Funds LLC, Spring Creek Capital LLC, Jefferies Group LLC and ARK Investment Management LLC.
How do I buy shares of Mazor Robotics?
Shares of MZOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mazor Robotics' stock price today?
One share of MZOR stock can currently be purchased for approximately $58.21.
How big of a company is Mazor Robotics?
Mazor Robotics has a market capitalization of $1.53 billion and generates $64.95 million in revenue each year. The medical instruments supplier earns $-12,410,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Mazor Robotics employs 194 workers across the globe.
What is Mazor Robotics' official website?
How can I contact Mazor Robotics?
Mazor Robotics' mailing address is 5 SHACHAM STREET NORTH INDUSTRIAL PARK, CAESAREA L3, 3088900. The medical instruments supplier can be reached via phone at 972-4618-7101 or via email at [email protected]
MarketBeat Community Rating for Mazor Robotics (NASDAQ MZOR)
MarketBeat's community ratings are surveys of what our community members think about Mazor Robotics and other stocks. Vote "Outperform" if you believe MZOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MZOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
